Category: Contract Manufacturing

Favorable Demand Dynamics within the Ophthalmic Drugs Contract Manufacturing Market

In the past two decades, advances in optometry, along with an increased understanding of human eye and vision care, have led scientists to develop innovative treatment methods in order to treat eye disorders and to overcome the limitations offered by conventional medical practices. The current ophthalmic diseases treatment landscape is characterized by a number of

Outsourcing has become a popular trend in ophthalmic drug development domai

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers. Over 240 companies

Microbiome-based Live Biotherapeutics Contract Manufacturing: Rising Opportunities for Specialized CMOs / CDMOs

What is the current development pipeline of microbiome-based live biotherapeutics? With over 85 products under preclinical and clinical development, the current development pipeline of microbiome-based live biotherapeutics has several promising candidates, which are anticipated to get commercialized over the next few years. Hence, the demand for R&D and manufacturing services for such products is anticipated

How COVID-19 Poses a Sharp Challenge on China Biopharmaceutical Contract Manufacturing Market?

China, epicenter of the COVID-19, is the world’s second largest pharmaceutical market and accounts for 20 % of the global output of APIs. With over 25 biologics and biosimilar products approved till date and close to 1,000 clinical trials, investigating a variety of biologics and biosimilars, being underway in this region, China’s biopharma market is

Continuous Manufacturing: Solution to Pharmaceutical Manufacturing Industry’s COVID-19 Concerns

The ongoing COVID-19 crisis has put the pharmaceutical manufacturing supply chain under close scrutiny. The overdependence of the US on China and India to meet its API demand has been the talk of the town. However, with the number of infected cases in the US surpassing that of China, the focus has shifted from discussing

Microbiome Contract Manufacturing: Time to Push the Increase Capacity Button

The interest in the trillions of microbiome present in the human body has attracted a lot of research effort in the microbiome domain. The first such effort at a large scale was The Human Microbiome Project, conducted by the National Institutes of Health in the United States, which characterized the microbial communities at five major

Cell Therapy and The Rise of Novel Technologies

Roots Analysis has actively tracked the developments in the field of cell therapy and gene therapies. The team has focused on identifying the key challenges that are hampering the growth of these revolutionary therapies. To identify the challenges, the team has interviewed several stakeholders involved in cell therapy development and manufacturing. In addition, a recent

Cell Therapy Manufacturing Update: United Therapeutics Receives Permit

As per recent news coverage, United Therapeutics has received a permit for $9.5 million build-out of its cell therapy facility on the second floor of Mayo Clinic’s Discovery and Innovation Building. What is the area of the facility:  The facility will have a total of 21,843-square-foot space. What are the capabilities at the facility:  The facility will house

Growing Cell and Gene Therapy Market: Vector Manufacturers Make Merry

Cell and Gene Therapy are the new entrants in the pharma Superstar Club. They are selling tickets faster than a Queen’s concert in the 1980s. In fact, as per the Alliance of Regenerative Medicine’s recent findings, there has been more than 75% year on year increment in funding to support the development of various cell and gene therapies.